BACKGROUND: In this study, the development and validation of a cycle-based prediction model for severe anemia [i.e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described. MATERIALS AND METHODS: Data on 536 European patients who were receiving palliative chemotherapy were prospectively collected as part of the European Cancer Anemia Survey [Ludwig et al., Eur J Cancer 40:2293-2306, 2004]. The patient sample was then randomly divided into two-thirds model derivation and one-third validation sample. A third external sample consisting of 76 patients treated at the Toronto Sunnybrook Regional Cancer Centre was separately used to externally validate the model. Multivariable logistic regression techniques were applied to develop the initial model. A risk scoring system based on the regression parameters was then created ranging from 0 to 15. RESULTS: Precycle Hb, patient body surface area, advanced age, poor performance status, recurrent or persistent disease, and the use of platinum or gemcitabine-based chemotherapy were identified as important predictors for anemia. A prechemotherapy risk score of >or=8 to <10 was identified as the optimal cut off to maximize the sensitivity (83.1%) and specificity (67.8%) of the prediction tool. Patients with a score of >or=8 would be considered at high risk for developing anemia after a particular cycle of chemotherapy. DISCUSSION: We developed and validated an anemia prediction tool for advanced stage NSCLC patients receiving palliative chemotherapy. To make the model available for easy use and access, we have incorporated it on to our risk prediction website: http://www.PredictPatientEvents.com . It is hoped that this risk model will enhance patient care by optimizing the frequency of Hb testing and/or the use of preventative therapies.
BACKGROUND: In this study, the development and validation of a cycle-based prediction model for severe anemia [i.e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described. MATERIALS AND METHODS: Data on 536 European patients who were receiving palliative chemotherapy were prospectively collected as part of the European Cancer Anemia Survey [Ludwig et al., Eur J Cancer 40:2293-2306, 2004]. The patient sample was then randomly divided into two-thirds model derivation and one-third validation sample. A third external sample consisting of 76 patients treated at the Toronto Sunnybrook Regional Cancer Centre was separately used to externally validate the model. Multivariable logistic regression techniques were applied to develop the initial model. A risk scoring system based on the regression parameters was then created ranging from 0 to 15. RESULTS: Precycle Hb, patient body surface area, advanced age, poor performance status, recurrent or persistent disease, and the use of platinum or gemcitabine-based chemotherapy were identified as important predictors for anemia. A prechemotherapy risk score of >or=8 to <10 was identified as the optimal cut off to maximize the sensitivity (83.1%) and specificity (67.8%) of the prediction tool. Patients with a score of >or=8 would be considered at high risk for developing anemia after a particular cycle of chemotherapy. DISCUSSION: We developed and validated an anemia prediction tool for advanced stage NSCLCpatients receiving palliative chemotherapy. To make the model available for easy use and access, we have incorporated it on to our risk prediction website: http://www.PredictPatientEvents.com . It is hoped that this risk model will enhance patient care by optimizing the frequency of Hb testing and/or the use of preventative therapies.
Authors: R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Enrico Cortesi; Pere Gascón; David Henry; Timothy Littlewood; Robert Milroy; Paolo Pronzato; Uwe Reinhardt; Daniel Shasha; Nicholas Thatcher; Peter Wilkinson Journal: Oncology Date: 2005 Impact factor: 2.935
Authors: Marcus A Neubauer; Craig H Reynolds; Marcos G Joppert; Thomas Whitaker; Habib Ghaddar; Thomas A Marsland; Lina Asmar Journal: Clin Lung Cancer Date: 2005-01 Impact factor: 4.785
Authors: Pere Gascón; José Almenárez; Ángel Artal; Carlos Camps; José Luis Fírvida; Pilar Garrido; José Luis González Larriba; Joaquín Montalar Journal: Clin Transl Oncol Date: 2011-05 Impact factor: 3.405
Authors: Maen Hussein; Marina Maglakelidze; Donald A Richards; Marielle Sabatini; Todd A Gersten; Keith Lerro; Ivan Sinielnikov; Alexander Spira; Yili Pritchett; Joyce M Antal; Rajesh Malik; J Thaddeus Beck Journal: Cancer Manag Res Date: 2021-08-09 Impact factor: 3.989
Authors: Lorenzo Gianni; Bernard F Cole; Ilaria Panzini; Raymond Snyder; Stig B Holmberg; Michael Byrne; Diana Crivellari; Marco Colleoni; Stefan Aebi; Edda Simoncini; Olivia Pagani; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Alan S Coates; Alberto Ravaioli Journal: Support Care Cancer Date: 2007-07-13 Impact factor: 3.603
Authors: Parth Sharma; Josh Thomas Georgy; Anand George Andrews; Ajoy Oommen John; Anjana Joel; Raju Titus Chacko; Prasanna Samuel Premkumar; Ashish Singh Journal: Support Care Cancer Date: 2022-03-21 Impact factor: 3.359
Authors: Robert Pirker; Melissa Pirolli; Jane Quigley; Scott Hulnick; Jason Legg; Helen Collins; Johan Vansteenkiste Journal: Support Care Cancer Date: 2012-10-25 Impact factor: 3.603